BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma
NCT07927842, Phase 1, Not yet recruiting, Liping Dou
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma | ClinicalTrials.gov |
| NCT number | NCT07927842 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1 | ClinicalTrials.gov |
| Enrollment | 20 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Liping Dou | ClinicalTrials.gov |
| Conditions | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma | ClinicalTrials.gov |
| Interventions | SL4903 Injection (BCMA/GPRC5D Dual-Target Autologous CAR-T Cell Injection) | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Adverse Events | From SL4903 infusion through 3 months after infusion; long-term safety follow-up continues through 12 months | AEs are graded per NCI CTCAE v5.0 | ClinicalTrials.gov |
| Primary | Cytokine Release Syndrome | From SL4903 infusion through 3 months after infusion; long-term safety follow-up continues through 12 months | Cytokine release syndrome (CRS) is graded according to the ASTCT consensus criteria. | ClinicalTrials.gov |
| Primary | Immune Effector Cell-associated Neurotoxicity Syndrome | From SL4903 infusion through 3 months after infusion; long-term safety follow-up continues through 12 months | Immune effector cell-associated neurotoxicity syndrome (ICANS) is graded according to the ASTCT consensus criteria. | ClinicalTrials.gov |
| Secondary | Objective Response Rate | At Day 28 and Months 2, 3, 6, 12, 18, and 24 after SL4903 infusion | The proportion of participants achieving a partial response or better (ORR), assessed by the investigator according to the 2016 International Myeloma Working Group (IMWG) criteria. | ClinicalTrials.gov |
| Secondary | Complete Response Rate | At Day 28 and Months 2, 3, 6, 12, 18, and 24 after SL4903 infusion | The proportion of participants achieving a complete response (CR) or stringent complete response (sCR), per the 2016 IMWG criteria. | ClinicalTrials.gov |
| Secondary | Time to Response and Duration of Response | From SL4903 infusion through 24 months after treatment | Time to response (TTR), defined as the time from SL4903 infusion to first documented response, and duration of response (DOR), defined as the time from first documented response to disease progression or death, per the 2016 IMWG criteria. | ClinicalTrials.gov |
| Secondary | Progression-Free Survival | From SL4903 infusion through 24 months after treatment | Progression-free survival (PFS), defined as the time from SL4903 infusion to disease progression or death from any cause, whichever occurs first, per the 2016 IMWG criteria; PFS rates at 6, 9, 12, 18, and 24 months will also be estimated. | ClinicalTrials.gov |
| Secondary | Overall Survival | From SL4903 infusion through 24 months after treatment | Overall survival (OS), defined as the time from SL4903 infusion to death from any cause; OS rates at 6, 9, 12, 18, and 24 months will also be estimated. Participants who are alive at the last follow-up will be censored on the date of their last known survival status. | ClinicalTrials.gov |
| Secondary | Measurable Residual Disease (MRD) Negativity Rate | At Day 28 and Months 2, 3, 6, 12, 18, and 24 after SL4903 infusion | The proportion of participants achieving MRD negativity in bone marrow, assessed by flow cytometry, among responding participants. | ClinicalTrials.gov |
| Secondary | Peak Expansion of SL4903 CAR-T Cells in Peripheral Blood | Through Day 28 for AUCd0-28, Cmax, and Tmax; CAR-T persistence through 24 months after infusion | Peak expansion of SL4903 CAR-T cells in peripheral blood (Cmax, measured by both flow cytometry and qPCR), | ClinicalTrials.gov |
| Secondary | Time to Peak Expansion | Through Day 28 for AUCd0-28, Cmax, and Tmax; CAR-T persistence through 24 months after infusion | Time to Peak Expansion | ClinicalTrials.gov |
| Secondary | Area Under The Gene-copy Expansion Curve from Day 0 to Day 28 | Through Day 28 for AUCd0-28, Cmax, and Tmax; CAR-T persistence through 24 months after infusion | in vivo persistence of CAR-T cells, and the area under the gene-copy expansion curve from Day 0 to Day 28 (AUCd0-28). | ClinicalTrials.gov |
| Secondary | Pharmacodynamic Markers (Exploratory) | Through 24 months after SL4903 infusion | Proportion and absolute count of plasma cells in peripheral blood by flow cytometry, and peripheral blood cytokine levels (at least IL-6, IL-2, IL-10, IFN-gamma, and TNF-alpha) at prespecified time points. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)